دورية أكاديمية
SP70 is a novel biomarker of hepatocellular carcinoma.
| العنوان: | SP70 is a novel biomarker of hepatocellular carcinoma. |
|---|---|
| المؤلفون: | Wang L; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Shi H; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; NHC Contraceptives Adverse Reaction Surveillance Center, Jiangsu Health Development Research Center, Nanjing, China., Wei J; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Chen WX; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Jin YX; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Gu CR; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Mu Y; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Xu J; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China., Pan SY; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China. |
| المصدر: | Frontiers in oncology [Front Oncol] 2023 Apr 06; Vol. 13, pp. 1149397. Date of Electronic Publication: 2023 Apr 06 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Background: Tumor-specific protein 70 (SP70) was identified as a new biomarker associated with the proliferation and invasion of cancer cells. This study aimed to investigate the expression of SP70 in hepatocellular carcinoma (HCC) and assess its clinical value in the diagnosis and prediction of early HCC recurrence. Methods: A total of 1049 subjects from the First Affiliated Hospital of Nanjing Medical University were recruited in this study. Serum SP70, alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence II (PIVKA-II) were measured. The diagnostic performance for HCC was obtained using the receiver operating characteristic (ROC) curve, and recurrence-free survival (RFS) was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify predictive factors of RFS. Results: SP70 was highly expressed in HCC cells and HCC tissue. Serum SP70 levels in the HCC group were significantly higher than in the benign liver diseases group and healthy control group ( P <0.001). SP70 combined with AFP showed the best diagnostic performance (AUC=0.909, 95%CI [confidence interval]=0.890-0.929). Kaplan-Meier analysis revealed that patients with high SP70 levels had shorter median RFS than those with low SP70 levels ( P =0.003). In addition, high SP70 levels were significantly associated with shorter RFS ( P =0.037) in the AFP-negative subgroup. Univariate and multivariate analyses confirmed that preoperative serum SP70 level, serum AFP, tumor diameter and microvascular invasion were independent prognostic factors of RFS. Conclusion: SP70 is a promising biomarker in diagnosing HCC. High preoperative serum SP70 level is associated with an increased risk of early relapse and could be used as a valuable marker to predict early recurrence of HCC after resection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Wang, Shi, Wei, Chen, Jin, Gu, Mu, Xu and Pan.) |
| References: | Ann Intern Med. 2003 Jul 1;139(1):46-50. (PMID: 12834318) J Clin Oncol. 2011 Dec 20;29(36):4781-8. (PMID: 22105822) Sci Rep. 2020 Feb 13;10(1):2509. (PMID: 32054922) World J Gastroenterol. 2019 Jan 14;25(2):220-232. (PMID: 30670911) Thorac Cancer. 2020 Sep;11(9):2630-2638. (PMID: 32744429) Cancer Med. 2018 Jul;7(7):2925-2933. (PMID: 29767438) Medicine (Baltimore). 2017 Mar;96(11):e5811. (PMID: 28296720) Am J Gastroenterol. 2006 Mar;101(3):524-32. (PMID: 16542289) J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281) J Hepatol. 2019 Mar;70(3):440-448. (PMID: 30389551) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Cancer. 2018 Aug 1;124(15):3084-3104. (PMID: 29663340) Gut. 2019 Dec;68(12):2195-2205. (PMID: 31358576) Hepatology. 2012 Oct;56(4):1371-9. (PMID: 22535689) Cancers (Basel). 2020 Oct 31;12(11):. (PMID: 33142893) Gastroenterology. 2016 Apr;150(4):835-53. (PMID: 26795574) J Hepatol. 2020 Feb;72(2):250-261. (PMID: 31954490) Abdom Imaging. 2014 Aug;39(4):753-60. (PMID: 24699935) Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: 28622513) Clin Gastroenterol Hepatol. 2023 Feb;21(2):415-423.e4. (PMID: 35124267) Biomed Pharmacother. 2018 Jul;103:272-283. (PMID: 29656183) Nat Genet. 2014 Dec;46(12):1267-73. (PMID: 25362482) BMC Cancer. 2018 May 18;18(1):571. (PMID: 29776391) Front Oncol. 2021 Nov 10;11:726213. (PMID: 34900676) Gastroenterology. 2009 Jul;137(1):110-8. (PMID: 19362088) Liver Cancer. 2021 Sep 20;10(6):572-582. (PMID: 34950180) CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946) J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. (PMID: 27084040) Front Oncol. 2019 Dec 13;9:1372. (PMID: 31921636) PLoS One. 2012;7(3):e33009. (PMID: 22479355) Gut. 2014 May;63(5):844-55. (PMID: 24531850) Oncol Rep. 2017 Oct;38(4):2251-2258. (PMID: 28765910) J Hepatol. 2019 Jan;70(1):58-65. (PMID: 30213589) Onco Targets Ther. 2015 Dec 31;9:123-9. (PMID: 26770061) World J Surg Oncol. 2022 Apr 25;20(1):132. (PMID: 35468832) Nanoscale. 2017 Sep 21;9(36):13364-13383. (PMID: 28880034) Nat Genet. 2015 May;47(5):505-511. (PMID: 25822088) Liver Int. 2005 Feb;25(1):16-27. (PMID: 15698394) J Hepatol. 2015 Apr;62(4):848-54. (PMID: 25450201) Oncogene. 2010 Mar 25;29(12):1787-97. (PMID: 20023698) Cancer Manag Res. 2018 Jul 10;10:1947-1958. (PMID: 30022853) Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846) |
| فهرسة مساهمة: | Keywords: SP70; diagnostic performance; early recurrence; hepatocellular carcinoma; recurrence-free survival |
| تواريخ الأحداث: | Date Created: 20230424 Latest Revision: 20230425 |
| رمز التحديث: | 20230425 |
| مُعرف محوري في PubMed: | PMC10117782 |
| DOI: | 10.3389/fonc.2023.1149397 |
| PMID: | 37091138 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!